ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that the first participants have been dosed in a Phase 1 clinical trial ...
On March 18, 2026, OPKO Health appointed former chief financial officer Subbarao V. Uppaluri, Ph.D., as an independent director to fill a board vacancy created by the passing of director Richard ...
OPKO Health’s fair value estimate has been trimmed from $3.63 to $3.40, alongside a separate analyst price target shift to US$1.50, signaling a more cautious stance around the stock. Bullish voices ...
OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, supported by the potential of RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and strategic ...
For the quarter ended December 2025, OPKO Health (OPK) reported revenue of $148.5 million, down 19.1% over the same period last year. EPS came in at -$0.04, compared to $0.01 in the year-ago quarter.
OPKO Health is refocusing on drug development, with most pipeline assets in early stages and limited near-term catalysts. BioReference business transition continues, targeting profitability and ...
MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces ...
OPKO Health, Inc. (NASDAQ:OPK) is one of the High-Flying Penny Stocks to Buy. On March 12, Barrington lowered the firm’s price target on OPKO Health, Inc. (NASDAQ:OPK) from $2.25 to $1.50 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results